Vascular endothelial growth factor staining and elevated INR in advanced epithelial ovarian carcinoma

Journal of Surgical Oncology

Volumn 96, Issue 6, 2007, Pages 514-517

  Geisler, John P ^a   Miller, Greg A ^b   Broshears, John R ^c   Manahan, Kelly J ^a  

^a Indiana Women's Oncology PC   (United States)

^b St Vincent Hospitals   (United States)

^c St Vincent's Children's Hospital   (United States)

Author keywords

INR; Ovarian cancer; VEGF

Indexed keywords

VASCULOTROPIN;

ADVANCED CANCER; ANGIOGENESIS; ARTICLE; BLEEDING; BLOOD CLOTTING DISORDER; BLOOD VESSEL PERMEABILITY; CANCER SURGERY; CYTOREDUCTIVE SURGERY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; OVARY CARCINOMA; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN EXPRESSION;

FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INTERNATIONAL NORMALIZED RATIO; OVARIAN NEOPLASMS; PERIOPERATIVE CARE; PROTHROMBIN TIME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 35748971036     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.20839     Document Type: Article

References (35)

1. Jemal A, Siegel R, Ward E, et al.: Cancer Statistics, 2007 CA. Cancer J Clin 2007;57:43-66.
2. Brown JV, Karlan BY, Greenspoon JS, et al.: Perioperative coagulopathy in patients undergoing primary cytoreduction. Cancer 1993;71:2557-2561.
3. Glassman AB, Jones E: Thrombosis and coagulation abnormalities associated with cancer. Ann Clin Lab Sci 1994;24:1-5.
4. Glassman AB: Hemostatic abnormalities associated with cancer and its therapy. Ann Clin Lab Sci 1997;27:391-395.
5. Heindl B, Spannagl, M: Fresh plasma and concentrates of clotting factors for therapy of perioperative coagulopathy: What is known? Anaesthesist 2006;55:928-936.
6. Dzik WH: Predicting hemorrhage using preoperative coagulation screening assays. Cur Hematol Rep 2004;3:324-330.
7. Palo R, Capraro L, Hovilehto S, et al.: Population-based audit of fresh-frozen plasma transfusion practices. Transfusion 2006;46:1921-1925.
8. Dager WE, King JH, Regalia RC, et al.: Reversal of elevated international normalized ratios and bleeding with low-dose recombinant activated factor VII in patients receiving warfarin. Pharmacotherapy 2006;26:1091-1098.
9. Angelo M, Gutmann B, Adami M, et al.: Emergency correction of coagulation before major surgery in two elderly patients on oral anticoagulation. Thromb J 2007;5:1.
10. Dias S, Hattori K, Zhu Z, et al.: Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. J Clin Invest 2000;106:511-521.
11. Davidson B, Reich R, Lazarovici P, et al.: Expression and activation of the nerve growth factor receptor TrkA in serous ovarian carcinoma. Clin Cancer Res 2003;9:2248-2259.
12. Carney ME, Lancaster JM, Ford C, et al.: A population-based study of patterns of care for ovarian cancer: Who is seen by a gynecologic oncologist and who is not? Gynecol Oncol 2002;84:36-42.
13. Balli S, Fey MF, Hanggi W, et al.: Ovarian cancer: An institutional review of patterns of care, health insurance and prognosis. Eur J Cancer 2000;36:2061-2068.
14. Aletti GD, Dowdy SC, Gostout BS, et al: Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstet Gynecol 2006;107:77-85.
15. Harlan LC, Clegg LX, Trimble EL: Trends in surgery and chemotherapy for women diagnosed with ovarian cancer in the United States. J Clin Oncol 2003;21:3488-3494.
16. Munoz KA, Harlan LC, Trimble EL: Patterns of care for women with ovarian cancer in the United States. J Clin Oncol 1997;15:3408-3415.
17. Allen DG, Heintz AP, Touw FW: A meta-analysis of residual disease and survival in stage III and IV carcinoma of the ovary. Eur J Gynaecol Oncol 1996;16:349-356.
18. Grilli R, Minozzi S, Tinazzi A, et al.: Do specialists do it better: The impact of specialization on the processes and outcomes of care for cancer center. Annals Oncol 1998;9:365-374.
19. Eisenkop SM, Spirtos NM, Friedman RL, et al.: Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: A prospective study. Gynecol Oncol 2003;90:390-396.
20. Eisenkop S, Spirtos NM: Procedures required to accomplish complete cytoreduction of ovarian cancer: Is there a correlation with "biological aggressiveness" and survival. Gynecol Oncol 2001;82:435-441.
21. Geisler JP, Wiemann MC, Geisler HE: Optimal cytoreductive surgery in the elderly woman with stage IIIc serous cystadenocarcinoma of the ovary. J Pelvic Surg 1995;1:32-35.
22. Nasi MI, Castiglione M: Based on these findings, should we consider COX-2 expression as a predictive factor, and possibly also prognostic factor, for patients with ovarian cancer? Annals Oncol 2002;13:1169-1171.
23. Folkman J: A new link in ovarian cancer angiogenesis: Lysophosphatidic acid and vascular endothelial growth factor expression. J Natl Cancer Inst 2001;93:734-735.
24. Bamberger ES, Perrett CW: Angogenesis in eithelian ovarian cancer. Mol Pathol 2002;55:348-359.
25. Grove CS, Lee YCG: Vascular endothelial growth factor: The key mediator in pleural effusion formation. Curr Opin Pulm Med 2002;8:294-301.
26. Ferrario A, Fisher AM, Rucker N, et al.: Celecoxib and NS-398 enhance photodynamic therapy by increasing in vitro apoptosis and decreasing in vivo inflammatory and angiogenic factors. Cancer Res 2005;65:9473-9478.
27. Takahashi H, Shibuya M: The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin Sci 2005;109:227-241.
28. Aslam N, Marino CR: Malignant ascites: New concepts in pathophysiology, diagnosis, and management. Arch Int Med 2001;161:2733-2737.
29. Cooper BC, Ritchie JM, Broghammer CL, et al.: Preoperative serum vascular endothelial growth factor levels: Significance in ovarian cancer. Clin Cancer Res 2002;8:3193-3197.
30. Poon RTP, Fan ST, Wong J: Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol 2001;19:1207-1225.
31. Inan S, Vatansever S, Celik-Ozenci C, et al.: Immunolocalizations of VEGF, its receptors flt-1, KDR, and TGF-beta's in epithelial ovarian tumors. Histol Histopathol 2006;21:1055-1064.
32. Rudlowski C, Pickart AK, Fuhljahn C, et al.: Prognostic significance of vascular endothelial growth factor expression in ovarian cancer patients: A long-term follow-up. Int J Gynecol Cancer 2006;16S1:183-189.
33. Harrison TD, Laskosky J, Jazaeri O, et al.: "Low-dose" recombinant activated factor VII results in less blood and blood product use in traumatic hemorrhage. Trauma-Injury Inf Crit Care 2005;59:150-154.
34. Horlocker TT, Nuttall GA, Dekutoski MB, et al.: The accuracy of coagulation tests during spinal fusion and instrumentation. Anesth Analgesia 2001;93:33-38.
35. Shore-Lesserson L: Evidence based coagulation monitors: Heparin monitoring, thromboelastography, and platelet function. Semin Cardiothorac Vasc Anesth 2005;9:41-52.